Clinical Trial Update: Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial completed evaluating uptake of the radiotracer [68Ga]P16-093 in metastatic prostate cancer and metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Renal Cell Carcinoma

Drugs mentioned

• 68Ga-P16-093 (P16-093 Ga-68 radiopharmaceutical)

Snippet

Sponsor: Five Eleven Pharma, Inc. | Conditions: Prostate Cancer, Renal Cancer | Phase 1 | Status: COMPLETED